Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64826-issels-recurrent-lung-cancer-responds-to-integrative-immunotherapy
By reprogramming a 7–year–old girl’s own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom–designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child’s doctors found that she had no evidence of cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/50777-chop-engineered-immune-t-cell-therapy-anticancer-effect-in-children
Based on an original story by Roberto Stopello and written by Indira Páez, the new season of the Super Series™ unfolds within the painful context of the undocumented immigrants who cross the border from Mexico to the United States in search of the American Dream. “Señora Acero, La Coyote” continues the story of Vicenta Acero (Carolina Miranda), a strong woman who has carved a path for herself in a male-dominated world and fights for better treatment of the many immigrants who struggle to cross one of the world’s longest borders. In the new season, La Coyote faces enemies on both sides of the law who are out for revenge and to destroy the Acero Quintanilla dynasty.
To view the multimedia release go to:
https://www.multivu.com/players/English/8202051-telemundo-senora-acero-la-coyote/
GetWellNetwork®, the health care technology company that pioneered Interactive Patient Care™, introduced today a model for enhanced patient and family engagement that mirrors the fundamentals of precision medicine. Supported by The Patient’s Platform™ — a cross-continuum suite of integrated solutions, tools and strategies — Precision Engagement™ delivers uniquely personalized care guided by a person’s ability to take an active role in their health journey.
To view the multimedia release go to:
https://www.multivu.com/players/English/8151751-getwellnetwork-precision-engagement-the-patient-platform/
WebMD Health Corp. (Nasdaq: WBMD), the leading source of health information, today released Marijuana on Main Street, a special report that provides an in-depth look at the debate over medical marijuana. As numerous states consider bills to legalize medical marijuana, WebMD surveyed nearly 3,000 consumers and Medscape surveyed more than 1,500 doctors about their attitudes regarding legalization, marijuana as a potential treatment option, and the perceived risks and benefits of its use to help shed light on this evolving issue.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7040258-webmd-medscape-medical-marijuana-report
Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11.
BELVIQ was approved by the U.S. Food and Drug Administration on June 27, 2012 to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m² or greater (obese), or BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes your risk of heart problems or stroke, or of death due to heart problems or stroke.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults
Until recently, cancer patients looking for the most precise form of proton radiation therapy – “pencil-beam scanning” – had to narrow their search to about a half dozen centers in the United States that offer this treatment on a limited basis.
Today’s opening of the Scripps Proton Therapy Center in San Diego, Calif., marks the first time that a proton center in the United States is treating patients exclusively with this ultra-accurate technology, in every treatment room.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65691-scripps-proton-therapy-center-san-diego-precise-cancer-care
To promote the science behind obesity prevention and treatment, The Obesity Society (TOS) and the American Society for Metabolic and Bariatric Surgery (ASMBS) are combining resources to host the world’s pre-eminent meeting on obesity, ObesityWeek(SM) 2013, Nov. 11-16, at the Georgia World Congress Center in Atlanta, Georgia. For the first time, both organizations will co-locate their respective annual meetings under one roof for the most comprehensive agenda in obesity research, treatment and prevention.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55494-tos-and-asmbs-host-obesity-week-2013
Upsher-Smith Laboratories, Inc., today announced the addition of the topic Sleep Disorders and Epilepsy to its epilepsy-focused educational website, Epilog.us. The site now features a review of the relationship between epilepsy and sleep disorders.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59872-epilog-us-expert-discussion-comorbidity-of-sleep-disorders-and-seizures
The European Parkinson’s Disease Association (EPDA) has launched the third and final booklet in its Life with Parkinson’s series. This latest edition concludes a four-year awareness campaign, which aims to highlight the lack of understanding and knowledge concerning Parkinson’s that exists throughout Europe today. The booklet’s launch, in Amsterdam, the Netherlands, was one of the many activities in a weekend dedicated to celebrating the organisation’s 20th anniversary year and its commitment to improving the lives of people with Parkinson’s (PwPs).
To view Multimedia News Release, go to http://www.multivu.com/mnr/56619-epda-launches-life-with-parkinsons-booklet
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
